NCT06322667 A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
| NCT ID | NCT06322667 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Eisai Co., Ltd. |
| Condition | Alzheimer's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2024-02-14 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2024-02-14 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
Eligibility Criteria
Inclusion Criteria: * All participants who are treated with lecanemab in routine clinical practice Exclusion Criteria: * None
Contact & Investigator
Eisai Inquiry Service.
✉ eisai-chiken_hotline@hhc.eisai.co.jpFrequently Asked Questions
Who can join the NCT06322667 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alzheimer's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06322667 currently recruiting?
Yes, NCT06322667 is actively recruiting participants. Contact the research team at eisai-chiken_hotline@hhc.eisai.co.jp for enrollment information.
Where is the NCT06322667 trial being conducted?
This trial is being conducted at Hiroshima, Japan, Kyoto, Japan, Tokyo, Japan.
Who is sponsoring the NCT06322667 clinical trial?
NCT06322667 is sponsored by Eisai Co., Ltd.. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.